Edwards Lifesciences to Acquire Innovalve
15 Julio 2024 - 8:00AM
Business Wire
Edwards Lifesciences (NYSE: EW) today announced it has exercised
its option to acquire Innovalve Bio Medical Ltd., an early-stage
transcatheter mitral valve replacement (TMVR) company, following
its initial investment in 2017. Since that time, Innovalve has
demonstrated progress in its program with promising early clinical
experience.
Combined with Edwards’ existing mitral innovations, the
acquisition enhances the company’s TMVR technologies to address
large unmet structural heart patient needs and support sustainable
long-term growth. Innovalve will join the transcatheter mitral and
tricuspid therapies (TMTT) product group, led by corporate vice
president, Daveen Chopra.
“Building on our learnings of the complexity of mitral disease,
we know there is a need for a differentiated range of therapies for
these patients,” said Chopra. “Edwards’ SAPIEN M3 remains on track
to become the first approved transfemoral TMVR system in Europe by
the end of 2025. We believe the Innovalve technologies, paired with
Edwards’ deep mitral expertise, will enable a TMVR platform that
will expand the treatable population.”
Edwards is developing a portfolio of transcatheter repair and
replacement therapies designed to address mitral and tricuspid
valve diseases. The company is committed to transforming the
treatment of mitral and tricuspid patients, supported by a robust
body of clinical evidence.
The acquisition is expected to close by the end of 2024.
About Edwards
Lifesciences
Edwards Lifesciences is the global leader of patient-focused
innovations for structural heart disease and critical care
monitoring. We are driven by a passion for patients, dedicated to
improving and enhancing lives through partnerships with clinicians
and stakeholders across the global healthcare landscape. For more
information, visit www.edwards.com and follow us on Facebook,
Instagram, LinkedIn, X and YouTube.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
We intend the forward-looking statements contained in this Proxy
Statement to be covered by the safe harbor provisions of such Acts.
These forward-looking statements can sometimes be identified by the
use of forward-looking words, such as “may,” “might,” “believe,”
“will,” “expect,” “project,” “estimate,” “should,” “anticipate,”
“plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,”
“aspire,” “confident” and other forms of these words and include,
but are not limited to, statements made by Mr. Chopra and
statements regarding expected technology performance, product and
therapy benefits, patient outcomes, treatable population,
probability of approval by government authorities in Europe,
performance of Innovalve’s technology as a basis for or in support
of a TMVR platform, synergy between Innovalve’s technology and
products and Edwards’ expertise, products, and operations, Edwards’
commitment to developing a portfolio of transcatheter repair and
replacement therapies and to expanding or transforming patients’
treatments, other objectives and expectations, and other statements
that are not historical facts. Forward-looking statements are based
on estimates and assumptions made by management of the company and
are believed to be reasonable, though they are inherently uncertain
and difficult to predict. Our forward-looking statements speak only
as of the date on which they are made, and we do not undertake any
obligation to update any forward-looking statement to reflect
events or circumstances after the date of the statement. Investors
are cautioned not to unduly rely on such forward-looking
statements.
Forward-looking statements involve risks and uncertainties that
could cause actual results or experience to differ materially from
that expressed or implied by the forward-looking statements.
Factors that could cause actual results or experience to differ
materially from that expressed or implied by the forward-looking
statements include, but are not limited to: (i) Edwards may be
unable to close the acquisition of Innovalve in a timely manner or
at all, which may materially and adversely affect Edwards’ business
and the price of Edward’ common stock; (ii) uncertainty as to the
timing of closing of the acquisition of Innovalve; (iii) the
occurrence of any event, change or other circumstance that could
cause Edwards to abandon the acquisition of Innovalve; (iv) risks
related to disruption of management’s attention from Edwards’
ongoing business operations; (v) the effect of the announcement or
the pendency of the acquisition of Innovalve on Edwards’
relationships with its customers, operating results and business
generally; (vi) potential significant transaction costs associated
with the acquisition of Innovalve; (vii) the outcome of any legal
proceedings or regulatory actions to the extent initiated against
Edwards or others related to the acquisition of Innovalve; (viii)
the ability of Edwards to execute on its strategy and achieve its
goals and other expectations after the closing of the acquisition
of Innovalve; (ix) legal, regulatory, tax and economic developments
affecting Edwards’ business; (x) the unpredictability and severity
of catastrophic events, including, but not limited to, acts of
terrorism, outbreak of war or hostilities or current or future
pandemics or epidemics, as well as Edwards’ response to any of the
aforementioned factors; and (xi) other risks detailed in Edwards’
filings with the SEC, which may be found at edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, Edwards
SAPIEN, Edwards SAPIEN M3, SAPIEN, and SAPIEN M3 are trademarks of
Edwards Lifesciences Corporation. All other trademarks are the
property of their respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240715027456/en/
Media Contact: Loree Bowen, 949-250-0554 Investor
Contact: Mark Wilterding, 949-250-6826
Edwards Lifesciences (NYSE:EW)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Edwards Lifesciences (NYSE:EW)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024